The WHO classification emphasizes the importance of detecting specific gene fusions, such as PAX3-FOXO1 in ARMS and NCOA2 rearrangements in spindle cell variants, to help differentiate RMS subtypes and predict patient outcomes. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.